DrugsNews.net

Drugs Xagena

The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the 1st-line treatment of adult patients with lo ...


Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab ) when used as first-line treatments for urothelial cancer ( cancer of the ...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol, FF/VI ), an inhaled corticosteroid ( ICS ) / long-acting beta2-agonist ...


The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma ( aRCC ). ...


The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for use as a maintenance therapy for patients with Platinum-sensitive relapsed high-grade, epithe ...


The U.S. Food and Drug Administration ( FDA ) has approved Tafinlar ( Dabrafenib ) and ( Trametinib ), administered together, for the treatment of anaplastic thyroid cancer ( ATC ) that cannot be remo ...


The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious c ...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg, BIC/FTC/TAF ), a once-daily single tablet regimen ( STR ) for ...


The FDA ( U.S. Food and Drug Administration ) has approved Lutathera ( Lutetium Lu 177 dotatate ) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastr ...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients with stage III non-small cell lung cancer ( NSCLC ) whose tumors are not able to be surg ...


The FDA ( U.S. Food and Drug Administration ) has approved Erleada ( Apalutamide ) for the treatment of patients with prostate cancer that has not spread ( non-metastatic ), but that continues to grow ...


The FDA ( U.S. Food and Drug Administration ) has approved Imfinzi ( Durvalumab ) for the treatment of patients with stage III non-small cell lung cancer ( NSCLC ) whose tumors are not able to be surg ...


European Commission ( EC ) has granted marketing authorisation for Ocrevus ( Ocrelizumab ) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and fo ...


The FDA ( U.S. Food and Drug Administration ) has approved Nerlynx ( Neratinib ) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cance ...


The European Commission ( EC ) has approved Alecensa ( Alectinib ), a second-generation ALK inhibitor, for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer ( ...